Q-omics provides the consensus-scored IGLC2 profile across patient tissues and cancer cell-line models. IGLC2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGLC2 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, IGLC2 RNA expression shows 16,524 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where IGLC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLC2 survival associations across molecular data types. IGLC2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLC2 RNA expression–survival associations across cancer types. High IGLC2 expression shows favorable associations in HNSC, SKCM, BRCA, CESC, OV and SARC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGLC2 RNA expression.
This table summarizes IGLC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGLC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLC2 shows lower tumor expression in COAD, LIHC and BRCA and higher tumor expression in LUAD, KIRC and ESCA. The COAD box plot shows higher IGLC2 RNA expression in normal versus tumor tissue (log2 FC = −3.881, t-test p < 0.001).
This table shows molecular features associated with IGLC2 in patient tissues and cancer cell lines. In patient samples, IGLC2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
